Background Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is
limited by bleeding concerns. Asundexian, a novel, oral small molecule activated …

Background: Guidelines recommend warfarin as the standard of care for patients with atrial
fibrillation (AF) at moderate or high risk for stroke. This phase II study assessed the effects of …

Summary Background The Apixaban for Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE) trial showed that apixaban is better than warfarin at …

Background The perceived risk of serious bleeding is an obstacle to the use of oral
anticoagulation in East Asia. The efficacy and safety of apixaban in East Asian patients with …

Abstract Aim In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial, apixaban compared with warfarin reduced the risk of …

Aims The risk of stroke in patients with atrial fibrillation (AF) increases with age. In the
ARISTOTLE trial, apixaban when compared with warfarin reduced the rate of stroke, death …

Aims It is uncertain whether the benefit from apixaban varies by type and duration of atrial
fibrillation (AF). Methods and results A total of 18 201 patients with AF [2786 (15.3%) with …

Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …